No Data
No Data
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares
Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's Is How to Trade
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product
Buy Rating Upheld for Terns Pharmaceuticals Amid Strong Prospects for TERN-701 and Financial Stability
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
FOSTER CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
FOSTER CITY, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product
No Data